Luboshitzky R, Wagner O, Lavi S, Herer P, Lavie P
Endocrine Institute, Haemek Medical Center, Afula, Israel.
Clin Endocrinol (Oxf). 1997 Oct;47(4):463-9. doi: 10.1046/j.1365-2265.1997.2881089.x.
We have recently demonstrated that GnRH deficient male patients have increased nocturnal melatonin secretion, whereas hypergonadotrophic hypogonadal males have decreased melatonin levels. We were interested in determining whether testosterone (T) treatment (when T levels were well matched with pubertal control values) has an effect on melatonin secretory profiles in these patients.
Prospective, controlled.
Six male patients with idiopathic hypogonadotrophic hypogonadism (IGD), six males with hypergonadotrophic hypogonadism due to Klinefelter's syndrome (KS) and seven controls. Patients were examined before and during the administration of 250 mg testosterone enanthate/month for four months.
Serum samples for melatonin levels were obtained every 15 minutes from 1990 to 0700 h in a controlled light-dark environment. The results of FSH, LH, T and oestradiol (E2) (determined at hourly intervals) and melatonin profiles, were compared with the pre-treatment values in each group, and with values obtained in the control group.
All 12 patients had low pre-treatment T levels (1.4 +/- 0.7 in IGD and 2.0 +/- 0.4 in KS vs. 19.8 +/- 2.3 nmol/l in controls) and attained normal levels after four months of T treatment (19.5 +/- 7 in IGD and 22.7 +/- 3.8 nmol/l in KS). Serum LH, FSH and E2 levels (11 +/- 4 IU/l, 24 +/- 10 IU/l and 113 +/- 12 pmol/l, respectively) were still elevated in KS during T treatment as compared with values in controls (2 +/- 1 IU/l, 2 +/- 1 IU/l and 67 +/- 4 pmol/l, respectively). In IGD, serum LH (0.12 +/- 0.1 IU/l) and FSH (0.16 +/- 0.2 IU/l) levels during T treatment were suppressed. Pretreatment melatonin levels in IGD were greater than those in age-matched pubertal controls while in KS, melatonin levels were lower than values in controls. Melatonin levels were equal in all 12 hypogonadal patients and controls when T levels were well matched. Mean (+/- SD) dark-time melatonin levels decreased from 286 +/- 18 to 157 +/- 26 pmol/l in IGD and increased from 92 +/- 19 to 183 +/- 48 pmol/l in KS (vs 178 +/- 59 pmol/l in controls). The integrated melatonin values decreased in IGD (from 184 +/- 14 to 102 +/- 21 pmol/min. 1 x 10(3)) and increased in KS (from 64 +/- 13 to 123 +/- 40, vs. 116 +/- 39 pmol/min. 1 x 10(3) in controls). No correlations were found between melatonin and LH, FSH or E2 levels.
These data indicate that male patients with GnRH deficiency have increased nocturnal melatonin secretion while in hypergonadotrophic hypogonadal males melatonin secretion is decreased. Testosterone treatment normalized melatonin concentrations in these patients. Taken together, the results suggest that GnRH, gonadotrophins and gonadal steroids modulate pineal melatonin in humans.
我们最近证实,促性腺激素释放激素(GnRH)缺乏的男性患者夜间褪黑素分泌增加,而高促性腺激素性性腺功能减退男性的褪黑素水平降低。我们感兴趣的是确定睾酮(T)治疗(当T水平与青春期对照值良好匹配时)是否对这些患者的褪黑素分泌情况有影响。
前瞻性、对照研究。
6例特发性低促性腺激素性性腺功能减退(IGD)男性患者、6例因克兰费尔特综合征(KS)导致的高促性腺激素性性腺功能减退男性患者和7名对照者。在给予每月250mg庚酸睾酮治疗4个月之前及治疗期间对患者进行检查。
在可控的明暗环境中,于19:00至07:00每15分钟采集一次血清样本检测褪黑素水平。将促卵泡生成素(FSH)、促黄体生成素(LH)、T和雌二醇(E2)(每小时测定一次)的结果以及褪黑素分泌情况与每组治疗前的值以及对照组获得的值进行比较。
所有12例患者治疗前T水平均较低(IGD组为1.4±0.7,KS组为2.0±0.4,而对照组为19.8±2.3nmol/L),T治疗4个月后达到正常水平(IGD组为19.5±7,KS组为22.7±3.8nmol/L)。与对照组值(分别为2±1IU/L、2±1IU/L和67±4pmol/L)相比,KS患者在T治疗期间血清LH、FSH和E2水平(分别为11±4IU/L、24±10IU/L和113±12pmol/L)仍升高。在IGD患者中,T治疗期间血清LH(0.12±0.1IU/L)和FSH(0.16±0.2IU/L)水平受到抑制。IGD患者治疗前褪黑素水平高于年龄匹配的青春期对照组,而KS患者的褪黑素水平低于对照组值。当T水平良好匹配时,所有12例性腺功能减退患者和对照组的褪黑素水平相等。IGD患者夜间平均(±标准差)褪黑素水平从286±18降至157±26pmol/L,KS患者则从92±19升至183±48pmol/L(对照组为178±59pmol/L)。IGD患者褪黑素综合值降低(从184±14降至102±2仁mol/min·1x10³),KS患者升高(从64±13升至123±40,对照组为116±39pmol/min·1x10³)。未发现褪黑素与LH、FSH或E2水平之间存在相关性。
这些数据表明,GnRH缺乏的男性患者夜间褪黑素分泌增加,而高促性腺激素性性腺功能减退男性的褪黑素分泌减少。睾酮治疗使这些患者的褪黑素浓度正常化。综上所述,结果提示GnRH、促性腺激素和性腺类固醇在人类中调节松果体褪黑素。